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subject areaB cells in Rheumatoid Arthritisype of data 1 ﬁgure, 3 tables, url to data
ow data was
acquiredSequencing, patient clinical characteristics linked to experimental dataata format Analyzed, raw
xperimental
factorsFcRL4þ and FcRL4- B cells were sorted from synovial ﬂuid and tissue from RA
patients. Synovial ﬂuid derived B cells were analysed for their gene expression
proﬁle by RNAseq. Immunoglobulin variable region genes from single sorted B
cells were sequenced and expressed as components of recombinant mono-
clonal antibodies. These were investigated for their reactivity with
autoantigens.xperimental
featuresData shown here include detailed clinical characteristics from anonymized
patients, the Ig isotype data generated from B cells sorted from four individual
patients, tables detailing variable gene region sequences from sorted cells
linked to the patient clinical characteristics and the sequence yields from
individual patients. We also supply a URL link to the RNAseq datasets sub-
mitted to GEO.ata source
locationBirmingham UKata accessibility https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc¼GSE94897
elated research
article1) Amara K, Clay E, Yeo L, Ramsköld D, Spengler J, Sippl N, Cameron JA,
Israelsson L,Titcombe PJ, Grönwall C, Sahbudin I, Filer A,Raza K, Malmström V,
Scheel-Toellner D.
B cells expressing the IgA receptor FcRL4 participate in the autoimmune
response in patients with rheumatoid arthritis. J Autoimmun. 2017. pii: S0896-
8411(16)30396-1. doi: 10.1016/j.jaut.2017.03.004 [Epub ahead of print]Value of the data
 First RNAseq dataset from FcRL4þ and FcRL4- B cells sorted from the synovial ﬂuid of patients with
rheumatoid arthritis. This will be valuable to researchers interested in the regulation of B cell
subpopulations and their functional role in RA.
 Ig subclass distribution in FcRL4þ and FcRL4- B cells inﬁltrating the rheumatoid joint. This gives
important information of the potential origins of these cells and their potential function in
the joint.
 The tables linking variable region sequences, gene usage, Ig isotypes and reactivity with citrulli-
nated autoantigens give insight into the immune response to citrullinated proteins on a single
cell basis.
1. Data
The data shown in this manuscript have been generated in a study of FCRL4þ and FcRL4- B cells
inﬁltrating the synovial ﬂuid and synovial tissue of RA patients. They include a link to the GEO dataset
of RNAseq gene expression proﬁles of these cells. Furthermore, the Ig isotype distribution of the B
cells for these populations is shown for four individual patients in Fig. 1. Table 1 gives detailed clinical
characteristics from the anonymized patients. These are linked to the data shown in Table 2, detailing
variable gene region sequences from sorted cells, the isotype usage and reactivity with citrullinated
proteins of these individual cells. Table 3 displays the number of sequences and recombinant
monoclonal antibodies generated from FcRL4þ and FcRL4- B cells from individual patients.
Fig. 1. Ig subclass distribution determined in single sorted FcRL4þ and FcRL4- B cells in four individual patients.
K. Amara et al. / Data in Brief 13 (2017) 356–3703582. Experimental design, materials and methods
More detailed information can be found in Ref. [1].
2.1. Experimental design
FcRL4þ and FcRL4- B cells were sorted from synovial ﬂuid and tissue from RA patients. Synovial
ﬂuid derived B cells were analysed for their gene expression proﬁle by RNAseq. Immunoglobulin
variable region genes from single sorted B cells were sequenced and expressed as components of
recombinant monoclonal antibodies. These were investigated for their reactivity with autoantigens.
Ampliﬁcation of sections of Ig constant regions was used to identify Ig isotype usage.
2.2. Materials and methods
Cells from 4 SF and 2 ST samples were stained for CD19 and FcRL4 and sorted either as single cells
or as cell populations. Individual IgH and IgL chain gene rearrangements were PCR-ampliﬁed inde-
pendently. For identiﬁcation of Ig isotypes, ampliﬁcation of IgH chains with reverse primers speciﬁc
for the constant regions of all human Ig classes and sequencing was used. Cloning of the Ig genes into
expression vectors and antibody production and puriﬁcation were performed. Antibody reactivity
against citrullinated peptides was determined by ELISA. For gene expression analysis RNA sequencing
was carried out on sorted FcRL4þ and FcRL4- B cells from 4 SF samples. Preampliﬁcation prior to
Illumina Truseq library preparation was performed using the SMARTer ampliﬁcation using olig(dT)
Table 1
Clinical characteristics of RA patients who provided synovial ﬂuid or synovial tissue. RF, rheumatoid factor; CCP, cyclic citrullinated peptide; CRP, C reactive protein; ESR, erythrocyte
sedimentation rate, DAS28, disease activity score 28, TJC, tender joint count, SJC swollen joint count, VAS visual analog score. Hydroxychlor., Hydroxychloroquine. NA not available.
Patient
identiﬁer














Figures Current disease mod-
ifying therapy
1 ST RA F 69 27 42 NA pos 0 18 5.6 12 3 80 1A, 1B, 2A, 2B, 3A,
3B, 3C, 4A, 4B
Adalimumab




3 SF RA M 72 72 0.23 neg neg 23 30 6.0 11 14 49 1A, 1B, 2A, 2B, 3A,
3B, 3C
Nil




5 SF RA F 40 40 0.23 pos pos 8 9 5.9 19 8 84 1A, 1B, 2A, 2B, 3A,
3B, 3C, 4A, 4B
Hydroxychlor.




7 SF RA M 68 56 12 NA NA 19 15 NA NA NA NA 1C Methotrexate
8 SF RA F 60 51 9 NA pos 45 13 NA 6 NA NA 1C Methotrexate
9 SF RA F 44 41 3 neg neg 13 29 4.95 7 3 45 1C Methotrexate
10 SF RA F 60 57 3 pos pos 20 55 7.05 15 10 85 1C Nil
11 SF RA M 39 34 5 NA NA NA NA NA NA NA NA 1C Etanercept
12 SF RA F 70 68 2 pos neg 142 21 4.8 5 2 73 1C Prednisolone
13 SF RA F 60 57 3 pos pos 122 104 5.88 2 4 91 1C Sulfasalazine
14 SF RA F 60 29 31 neg pos 57 28 6.75 16 11 89 1C Prednisolone
15 SF RA F 63 62 1 pos pos 30 60 4.13 1 2 22 1C Methotrexate,
prednisolone
16 SF RA M 54 54 0.23 neg neg 88 58 7.39 23 12 93 1C Nil
17 SF RA F 77 68 9 neg neg 71 62 NA NA NA NA 1C Methotrexate,
Prednisolone
18 SF RA M 72 56 16 pos pos 5 15 13 NA NA NA 5A, 5B Etanercept, Methotrex-
ate, Hydroxychlor.
19 SF RA F 32 31.2 0.8 pos pos 15 48 5.9 8 6 93 5A, 5B Nil
20 SF RA F 52 49 3 pos pos 13 34 6.54 14 10 78 5A, 5B Nil


















Sequence data and reactivity of monoclonal antibodies from FcRL4þ and FcRL4- B cells from RA patients.
Patient id Clone cell origin VH DH JH Ig SC VH-mut. VH CDR3 (aa) (þ) Length CCP2 CEP-1 cit-vim 60-75 cit-ﬁb 36-52
1 146þ .A06 ST (CD19þFcRL4þ) 3-33 2-2 6 IgG1 6 SRVGRVPDAVRYYFYGDV 3 18
146þ .A07 ST (CD19þFcRL4þ) 3-15 2-2 6 IgG1 29 ATDVFRTVVPVAIYSFYGLAV 1 21 pos pos pos neg
146þ .A08 ST (CD19þ FcRL4þ) 3-11 4-17 4 IgA1 10 ARGRWGLYGDYIFDS 2 15
146þ .A09 ST (CD19þ FcRL4þ) 5-51 3-22 3 IgA1 1 ARPHYYDSLDAFDI 2 14
146þ .A10 ST (CD19þ FcRL4þ) 3-33 6-13 4 IgA1 10 AREEGTGIVATDTESDFFDS 1 20 neg neg neg neg
146þ .A11 ST (CD19þ FcRL4þ) 1-18 3-10 5 IgA1 15 ARRPDSSQYSNWIDP 2 15 neg neg neg neg
146þ .A12 ST (CD19þ FcRL4þ) 3-23 6-13 5 IgA1 23 AKDDSPIATHSSWDS 2 15 neg neg neg neg
146þ .B01 ST (CD19þ FcRL4þ) 3-30-3 3-22 4 IgG1 35 VRGYCSSLSCSSFDS 1 15 neg neg neg neg
146þ .B02 ST (CD19þ FcRL4þ) 1-46 3-3 3 IgA1 20 ARAEGAVTIDDAFDI 1 15 neg neg neg neg
146þ .B03 ST (CD19þ FcRL4þ) 1-69 2-8 4 IgG1 17 ARHCNNGLCFYYFDY 2 15
146þ .B04 ST (CD19þ FcRL4þ) 3-30 4-11 4 IgG1 18 VKDAYRTQSPHFNNR 4 15
146þ .B05 ST (CD19þ FcRL4þ) 4-59 6-13 6 IgA1 21 ARAGSWFLYGMDV 1 13
146þ .B06 ST (CD19þ FcRL4þ) 4-4 3-10 3 IgG1 8 TSPQGGPGSYPHDAFDV 1 17 neg neg neg neg
146þ .B08 ST (CD19þ FcRL4þ) 1-2 3-9 4 IgG1 8 CARLRQDFDLLTGYQLGSYYFDY 2 23 neg neg neg neg
146þ .B12 ST (CD19þ FcRL4þ) 1-18 1-26 6 IgG3 26 AKDQWEAYYGLDV 1 13
146þ .C01 ST (CD19þ FcRL4þ) 3-23 2-2 6 IgA1 12 ARGKARYQLPTYFYYGMDV 3 19 neg neg neg neg
146þ .C04 ST (CD19þ FcRL4þ) 3-53 3-3 4 IgG1 14 ARAAVDFWSGYHLEY 2 15
146þ .C05 ST (CD19þ FcRL4þ) 5-51 6-13 6 IgA2 22 TRLGSWYLHYYGVDV 2 15
146þ .C06 ST (CD19þ FcRL4þ) 3-23 2-15 6 IgA1 15 AKRVVVASNHGYYSMDV 3 17
146þ .C08 ST (CD19þ FcRL4þ) 3-21 3-9 4 IgA1 20 ARDYDVFTGYPSHFFDH 3 17
146þ .C09 ST (CD19þ FcRL4þ) 3-21 2-15 6 IgG2 25 ARDRVDIVVKEPNFYYGVDV 3 20
146þ .C10 ST (CD19þ FcRL4þ) 4-34 1-26 4 IgA1 29 ANRRRYTTRFYFDF 4 14
146þ .D07 ST (CD19þ FcRL4þ) 3-23 3-10 1 IgA1 1 AKDRGVLRYFDWLH 4 14 neg pos pos neg
146þ .D08 ST (CD19þ FcRL4þ) 4-30-4 3-3 5 IgG2 36 ASSGFFGQPYNWFDR 1 15
146þ .D09 ST (CD19þ FcRL4þ) 3-48 3-3 4 IgG1 31 ARDTRDFWSGYYTYYFDY 2 18 pos neg neg neg
146þ .D10 ST (CD19þ FcRL4þ) 5-51 4-23 6 IgA1 19 ARLGKTTTVTSPYYYYYGMDV 2 21 neg neg neg neg
146þ .E01 ST (CD19þ FcRL4þ) 1-69 5-12 4 IgG1 12 ARDSGYDEGYYFDY 1 14 neg neg neg neg
146þ .E02 ST (CD19þ FcRL4þ) 3-9 1-26 4 IgA1 24 AKASGLTGSFYPLDH 2 15
146þ .E04 ST (CD19þ FcRL4þ) 4-34 2-15 4 IgG1 6 ARGGHRKYCSGGSCIYYFDY 4 20
146þ .E05 ST (CD19þ FcRL4þ) 3-11 5-12 3 IgA1 19 ARDDTVAFKDALDI 2 14 neg neg neg neg
146þ .E06 ST (CD19þ FcRL4þ) 1-69 1-1 4 IgA1 34 ARERALCAEGCPPGDD 2 16 neg pos neg neg
146þ .E07 ST (CD19þ FcRL4þ) 5-10-1 3-10 4 IgA2 16 ARVRTYYSAGTYPFDS 2 16
146þ .E08 ST (CD19þ FcRL4þ) 3-30 2-8 6 IgA1 21 AKAWGQLAGFALYFYGLDV 1 19
146þ .E12 ST (CD19þ FcRL4þ) 3-48 3-3 4 IgA1 26 ARINYDYWSDYARFLDS 2 17
146þ .F01 ST (CD19þ FcRL4þ) 4-30-4 3-10 4 IgG1 0 AFHLGEYGSGSYYDLDY 1 17 neg neg neg neg
146þ .F02 ST (CD19þ FcRL4þ) 4-38-2 6-13 3 IgA1 31 ARDRGYSTNWFLGFDV 2 16 neg neg neg neg
146þ .F04 ST (CD19þ FcRL4þ) 3-21 2-8 4 IgG1 19 AKPTVVYGPIDY 1 12
146þ .F08 ST (CD19þ FcRL4þ) 4-38-2 3-3 4 IgA1 22 AREFEHFGSGYFPVDY 2 16
















146þ .F10 ST (CD19þ FcRL4þ) 3-23 1-26 4 IgA1 20 ATDGEGVLFDE 0 11 neg neg neg neg
146þ .F11 ST (CD19þ FcRL4þ) 4-59 3-3 3 IgA1 22 ARVMTVFGVVPDAFDI 1 16
146þ .F12 ST (CD19þ FcRL4þ) 3-43 6-19 4 IgM 3 AKDISSTGWEYCFEN 1 15
146þ .G01 ST (CD19þ FcRL4þ) 3-20 1-26 4 IgA1 15 AKPSRVGAAADADY 2 14
146þ .G02 ST (CD19þ FcRL4þ) 4-31 3-3 5 IgG1 10 AREGVHATTFGMIDDQGWFDP 2 21 neg neg neg neg
146þ .G03 ST (CD19þ FcRL4þ) 1-46 1-14 6 IgG1 18 ARVSPGIRDDMDV 2 13 neg neg neg neg
146þ .G04 ST (CD19þ FcRL4þ) 3-30 7-27 4 IgG1 4 ARESGARWDVYFDY 2 14 neg neg neg neg
146þ .G05 ST (CD19þ FcRL4þ) 4-30-4 3-16 5 IgG1 36 ARAPPETLRGIVGNWFDP 2 18 neg pos pos neg
146þ .G06 ST (CD19þ FcRL4þ) 1-3 2-15 4 IgG1 14 VKDGGAGGANTFDH 2 14
146þ .G07 ST (CD19þ FcRL4þ) 3-33 5-24 4 IgA1 31 ARARRGDGYNQARYYYFDY 4 19 neg pos neg neg
146þ .G09 ST (CD19þ FcRL4þ) 1-18 6-19 3 IgA1 4 ARGWYSRGGGMDV 2 13 neg neg neg neg
146þ .G10 ST (CD19þ FcRL4þ) 1-18 3-16 4 IgG1 10 ARGWDPIVLPDYW 1 13
146þ .G11 ST (CD19þ FcRL4þ) 3-23 2-2 4 IgA1 27 AKSHLAHYVPVPAPFDF 3 17
146þ .G12 ST (CD19þ FcRL4þ) 1-3 1-26 6 IgM 1 TRDLLDRGKYYRVAGHFYGMDV 5 22
146þ .H02 ST (CD19þ FcRL4þ) 3-30 3-9 6 IgG3 33 ARDGGENEIVTGYFGWSNKPHSVKYYHGMDV 5 31
146þ .H05 ST (CD19þ FcRL4þ) 4-61 3-22 2 IgG2 3 ARHVGRLRRDSFTTRRTTDAADDWHIDL 8 28
146þ .H07 ST (CD19þ FcRL4þ) 3-30 1-26 5 IgG1 26 AKQSATMGPNRQPR 3 14 neg neg neg neg
146þ .H08 ST (CD19þ FcRL4þ) 4-34 6-13 5 IgA1 9 ARGFWDSGSWFDY 1 13
146þ .H09 ST (CD19þ FcRL4þ) 4-34 2-21 6 IgG1 8 ASKGGDSVGYHYYMDV 2 16 neg neg neg neg
146þ .H10 ST (CD19þ FcRL4þ) 1-18 3-3 5 IgA1 14 ARGRPSTFGVVRGFDP 3 16
146-.A03 ST (CD19þ FcRL4-) 3-30 4-17 4 IgG1 13 TRATRVNGNLNTFDY 2 15 neg neg neg neg
146-.A06 ST (CD19þ FcRL4-) 3-9 3-3 5 IgG1 14 AKDRFGELTDLTYVGWFDP 2 19 neg neg neg neg
146-.A07 ST (CD19þ FcRL4-) 5-10-1 3-10 5 IgA1 31 ARLDTSVIRGYNWFDP 2 16 neg neg neg neg
146-.B05 ST (CD19þ FcRL4-) 4-59 2-15 3 IgA1 7 ARHRGGSPTAFDI 3 13 neg neg neg neg
146-.B07 ST (CD19þ FcRL4-) 3-15 4-17 4 IgG1 17 TTVDDYECHDY 1 11
146-.B11 ST (CD19þ FcRL4-) 4-4 2-15 4 IgG1 17 ARVSEAYFDPFYYDNN 1 16
146-.B12 ST (CD19þ FcRL4-) 1-18 3-9 4 IgG1 30 ARAPGSLRYYDWVSLYEEGDH 3 21 neg neg neg neg
146-.C01 ST (CD19þ FcRL4-) 1-46 3-10 3 IgA1 20 TSPQGGPGSYPHDAFDV 1 17 neg neg neg neg
146-.C07 ST (CD19þ FcRL4-) 1-46 3-3 6 IgG1 29 ARVTTFESGPNDFGVPDHFYYVLDV 2 25 neg neg neg neg
146-.C10 ST (CD19þ FcRL4-) 4-34 1-26 4 IgA1 32 ANRRRCTTRFYFDF 4 14 neg neg neg neg
146-.D03 ST (CD19þ FcRL4-) 3-23 2-8 4 IgG1 22 AKPLVYARLYFYYDLDY 2 17 neg neg neg neg
146-.D05 ST (CD19þ FcRL4-) 3-48 3-22 4 IgG1 0 VRDSPGWGFRYYDY 2 14 neg neg neg neg
146-.D06 ST (CD19þ FcRL4-) 4-30-4 3-22 4 IgM 3 AAYPGDNSGRHLISPPFDN 2 19
146-.D09 ST (CD19þ FcRL4-) 4-30-4 3-22 4 IgG1 26 AAYGSYDRHLISPNPFYYDN 2 20 neg neg neg neg
146-.E04 ST (CD19þ FcRL4-) 3-7 6-13 6 IgG2 25 VSQQVVPC 0 8
146-.E05 ST (CD19þ FcRL4-) 3-7 6-13 6 IgA2 31 VSGGLQQYDVVPC 0 13
146-.E06 ST (CD19þ FcRL4-) 4-34 2-15 4 IgA1 8 ARGGHRKYCSGGSCIYYFDY 4 20 neg neg neg neg
146-.E07 ST (CD19þ FcRL4-) 3-74 2-2 6 IgG3 11 ARVQPQRVLVFYGMDV 2 16
146-.E08 ST (CD19þ FcRL4-) 3-11 4-17 4 IgG1 16 ARGAVTTPEYYFDY 1 14 neg neg neg neg
146-.E10 ST (CD19þ FcRL4-) 4-59 4-11 4 IgA1 25 ARLDYSPAFIFDS 1 13 neg neg neg neg
146-.E11 ST (CD19þ FcRL4-) 3-30-3 3-9 4 IgG1 13 ARGWERYYDWVAPGH 3 15
146-.F01 ST (CD19þ FcRL4-) 3-11 3-10 6 IgG4 26 ARGPSGMFGDLSPYFHYGVDV 2 21
146-.F04 ST (CD19þ FcRL4-) 5-10-1 2-15 5 IgG1 19 ARHGRGPSSWYDF 3 13
















Table 2 (continued )
Patient id Clone cell origin VH DH JH Ig SC VH-mut. VH CDR3 (aa) (þ) Length CCP2 CEP-1 cit-vim 60-75 cit-ﬁb 36-52
146-.F10 ST (CD19þ FcRL4-) 5-10-1 2-15 3 IgA1 19 AKAASRFDTFDI 2 12 neg neg neg neg
146-.F11 ST (CD19þ FcRL4-) 4-31 4-23 4 IgG2 22 TRGVIGLRGVPYYFDS 2 16
146-.G03 ST (CD19þ FcRL4-) 3-66 4 IgG1 17 RVDDTAVYYCARSPTGYDILTGPFDY 2 26
146-.G04 ST (CD19þ FcRL4-) 1-18 6-19 2 IgM 5 ARAVAVNWYFDL 1 12
146-.G05 ST (CD19þ FcRL4-) 3-48 5-18 3 IgM 0 ARGRKGYSYDAFDI 3 14
146-.G07 ST (CD19þ FcRL4-) 3-20 3-22 4 IgG1 12 ARGPPYYISSGYYFSFDS 1 18
146-.H01 ST (CD19þ FcRL4-) 4-59 2-21 4 IgA1 22 ARDDSLGGFDY 1 11 neg neg neg neg
146-.H02 ST (CD19þ FcRL4-) 3-23 3-22 5 IgM 2 AKYYDTSGSYKACDI 2 15
146-.H04 ST (CD19þ FcRL4-) 3-11 3-22 4 IgG1 25 ARGFYHDGTAYYHRNQSPFDH 5 21
Patient id Clone cell origin VH DH JH Ig SC VH-mut. VH CDR3 (aa) (þ) Length CCP2 CEP-1 cit-vim 60-75 cit-ﬁb 36-52
5 153þ .A04 SF (CD19þ FcRL4þ) 4-39 3-10 5 IgG1 6 ARLGGGYYYGSGYTRFDP 2 18 neg pos neg neg
153þ .A08 SF (CD19þ FcRL4þ) 3-13 3-9 1 IgA1 16 ATKPSHIYLRYFDWLLQGVRPLL 4 23
153þ .A09 SF (CD19þ FcRL4þ) 4-39 3-22 4 IgG1 2 ARYLREDYDISGLDY 2 15 neg neg neg neg
153þ .A10 SF (CD19þ FcRL4þ) 1-69 3-10 3 IgG1 12 ARRGYYYDYVWGDFRLTGPIEGAFDI 3 26 neg neg neg nrg
153þ .B05 SF (CD19þ FcRL4þ) 4-59 3-22 4 IgG3 13 AADNYYDSSEYSPYSFDS 0 18
153þ .B08 SF (CD19þ FcRL4þ) 3-48 3-3 6 IgG4 4 ASDKYDSWSRYVPYYGLDV 2 19
153þ .C03 SF (CD19þ FcRL4þ) 3-33 3-9 4 IgG2 8 ARGPDILTGGFYFDY 1 15
153þ .C04 SF (CD19þ FcRL4þ) 3-74 3-10 4 IgG1 6 VRGDLWFVELLYG 1 13 neg neg neg neg
153þ .C06 SF (CD19þ FcRL4þ) 1-18 3-22 4 IgA1 2 ARGSPYYYDSSGYYHYFDS 2 19 neg neg neg neg
153þ .C09 SF (CD19þ FcRL4þ) 4-59 3-3 6 IgA1 3 ARDKSADTLEWYYYYYGMDV 2 20
153þ .C10 SF (CD19þ FcRL4þ) 5-51 6-19 4 IgA1 4 APQSGSGWPYFDY 0 13
153þ .C12 SF (CD19þ FcRL4þ) 3-33 7-27 4 IgA1 16 ARHRGVTGLLNEPGDY 3 16 neg neg neg neg
153þ .D01 SF (CD19þ FcRL4þ) 3-33 2-21 4 IgA1 1 ARLLKTYCGGDCSLGY 2 16
153þ .D06 SF (CD19þ FcRL4þ) 5-51 3-3 6 IgA1 0 ARQYYDFWSDYYNSDYYYGMDV 1 22
153þ .D08 SF (CD19þ FcRL4þ) 4-34 3-10 6 IgA1 7 ARESHDHAELGYYYGMDV 3 18
153þ .E01 SF (CD19þ FcRL4þ) 4-59 6-13 4 IgA1 7 ASLPGSSTWFPFDY 0 14
153þ .E03 SF (CD19þ FcRL4þ) 3-21 3-10 4 IgA1 10 ARIRTKWFRRSSTMSSSFDY 5 20
153þ .E04 SF (CD19þ FcRL4þ) 1-69 2-15 6 IgG2 6 ARGRVPRIYYYYGMDV 3 16
153þ .E05 SF (CD19þ FcRL4þ) 1-2 3-22 3 IgG1 7 ARCDWGIYYYDSRAHGAFDF 3 20 neg neg neg neg
153þ .E07 SF (CD19þ FcRL4þ) 4-30-2 3-9 4 IgM 1 ARDQFFLAALDY 1 12
153þ .E11 SF (CD19þ FcRL4þ) 1-69 4-17 6 IgG2 4 AREDYGDDYYYYGMDV 1 16
153þ .F02 SF (CD19þ FcRL4þ) 3-66 3-22 3 IgG3 4 AREYNYDSSDAFDI 1 14
153þ .F04 SF (CD19þ FcRL4þ) 1-69 6-6 4 IgG2 5 ARSVQNLRYLGYYFDY 2 16
153þ .F07 SF (CD19þ FcRL4þ) 3-15 3-9 4 IgG1 5 TSSLVLRYFDWSTHSSDY 2 18 neg neg neg neg
153þ .G01 SF (CD19þ FcRL4þ) 3-15 1-1 4 IgG1 4 TTALNWNWDYYDY 0 13 neg neg neg neg
153þ .G07 SF (CD19þ FcRL4þ) 3-9 2-15 4 IgG2 9 VASYWRGYYFDY 1 12
153þ .H01 SF (CD19þ FcRL4þ) 3-33 3-3 6 IgG1 8 AKVAGYDFWSGPGGYYYSMDV 1 21
153þ .H02 SF (CD19þ FcRL4þ) 1-18 2-15 5 IgM 4 ARDSGGSWLDP 1 11
















153þ .H11 SF (CD19þ FcRL4þ) 3-11 4-11 6 IgA1 18 ARQSAYANYYYKGMDV 2 16
153-.A03 SF (CD19þ FcRL4-) 4-34 3-22 2 IgA1 14 ARGLTFSYYDSSGFGYYYWYFDL 1 23 neg neg neg neg
153-.A04 SF (CD19þ FcRL4-) 1-18 2-15 6 IgG1 7 ARDRHCSGGTCYPYHYGMDV 4 20
153-.A06 SF (CD19þ FcRL4-) 4-59 3-10 5 IgG4 5 ARTTTIRGVINWFDP 2 15
153-.A07 SF (CD19þ FcRL4-) 1-69 6-19 5 IgM 1 ARDFQRTSTVTRGIAVGSRFDP 4 22
153-.A12 SF (CD19þ FcRL4-) 5-51 2-2 3 IgG2 3 ARHLEYPHYVFDF 3 13
153-.B07 SF (CD19þ FcRL4-) 4-4 4-17 4 IgM 4 ARGGIWNDYGDFYPYYFDY 1 19
153-.C04 SF (CD19þ FcRL4-) 3-23 2-21 6 IgG2 6 AKEDYHFGRVD 3 11
153-.C07 SF (CD19þ FcRL4-) 1-18 6-13 5 IgG3 5 ARDGAMGHPDFWQQLVASWFDP 2 22
153-.C09 SF (CD19þ FcRL4-) 1-46 5-18 4 IgG1 8 AKSRGYSYGYFDY 2 13
153-.C11 SF (CD19þ FcRL4-) 5-51 5-12 6 IgG2 6 ARLPHYDWYYYYAMDV 2 16
153-.C12 SF (CD19þ FcRL4-) 4-39 3-16 4 IgG1 12 ARRSVYDANFDF 2 12 neg neg neg neg
153-.D11 SF (CD19þ FcRL4-) 1-8 3-22 5 IgM 2 ARAPYYYDSSGYYRGWFDP 2 19
153-.D12 SF (CD19þ FcRL4-) 3-21 5-24 4 IgA2 8 ARDLVEMATIIGHISY 2 16
153-.E12 SF (CD19þ FcRL4-) 4-4 2-15 4 IgG1 10 ARVVSEAAYFDN 1 12 neg neg neg neg
153-.F02 SF (CD19þ FcRL4-) 3-49 3-10 6 IgG1 12 SRVLRVVWGGRYYCMDV 3 17 neg neg neg neg
153-.F03 SF (CD19þ FcRL4-) 4-59 3-10 4 IgA1 5 ARVIMFTMVRGVQYYFDY 2 18
153-.F05 SF (CD19þ FcRL4-) 4-34 3-10 3 IgA1 5 ARGREVIMVRGVMKGTEAFDI 4 21
153-.F06 SF (CD19þ FcRL4-) 4-30 3-16 4 IgA1 8 ARGGREMLTIGGVVLSAFDF 2 20 neg neg neg neg
153-.F09 SF (CD19þ FcRL4-) 3-9 1-1 4 IgA1 7 VKDITWNRLWVFDS 2 14
153-.F10 SF (CD19þ FcRL4-) 4-4 1-14 4 IgG1 7 ARDKGNQPFFDY 2 12 neg neg neg neg
153-.F11 SF (CD19þ FcRL4-) 1-24 3-22 4 IgA1 14 ATVQNYFDSSGRVTPKSDFDY 2 21
153-.F12 SF (CD19þ FcRL4-) 3-48 3-16 4 IgG1 11 AGGRSYDYFDY 1 11 neg neg neg neg
153-.G02 SF (CD19þ FcRL4-) 3-9 2-15 4 IgM 1 AASYWRGYYFDY 1 12
153-.G06 SF (CD19þ FcRL4-) 3-7 3-10 4 IgG1 8 ARGESGGWFGEWVDY 1 15 neg neg neg neg
153-.G08 SF (CD19þ FcRL4-) 4-61 4-23 5 IgG2 5 ATYAMGYGGKGS 1 12
153-.G12 SF (CD19þ FcRL4-) 3-23 5-24 4 IgG1 4 AAPPDGYNSEGYFDY 0 15 neg neg neg neg
153-.H01 SF (CD19þ FcRL4-) 3-49 3-22 3 IgG2 3 CREEKDYYDRPRDAFDI 4 17
153-.H01 SF (CD19þ FcRL4-) 1-2 3-3 5 IgG3 5 ARGIGFNSWSGYPNWFDL 1 18
153-.H04 SF (CD19þ FcRL4-) 3-23 3-9 4 IgM 9 ATVSGWGGH 1 9
153-.H06 SF (CD19þ FcRL4-) 5-51 3-3 4 IgG1 7 ARHERYYDFWSGYYTEFDY 3 19 neg neg neg neg
153-.H09 SF (CD19þ FcRL4-) 1-18 3-16 4 IgG1 11 ARDLGFTFGGVMGY 1 14
153-.H10 SF (CD19þ FcRL4-) 1-8 3-3 6 IgG4 6 ARGINDFWSDYGMDV 1 15
153-.H11 SF (CD19þ FcRL4-) 3-9 6-6 6 IgG2 6 AKDKWKLAGASGGMDV 3 16
Patient id Clone cell origin VH DH JH Ig SC VH-mut. VH CDR3 (aa) (þ) Length
3 423þ .A01 SF, CD19þFcRL4þ 4-31 4-17 3 IgG1 6 ARGLDTHYGDYELDAFDI 2 18
423þ .A02 SF, CD19þ FcRL4þ 1-69 5-24 6 IgA1 21 TREISAKGANYNYYGMDV 2 18
423þ .A05 SF, CD19þ FcRL4þ 3-49 3-22 3 IgG1 12 ARDRWIVVVPEGGASDI 2 17
423þ .A06 SF, CD19þ FcRL4þ 1-69 5-18 4 IgG2 17 AREEAVDTAMLWYY 1 14
423þ .A07 SF, CD19þ FcRL4þ 1-69 5-24 4 IgG1 18 CAREGLYIATAFFDL 1 15
423þ .A11 SF, CD19þ FcRL4þ 4-30-4 3-22 3 IgA1 27 ATQSLGSSGYYRAFDI 1 16
423þ .A12 SF, CD19þ FcRL4þ 5-10-1 3-22 1 IgA2 22 AKDLLHFPYYYDSSDYYWPAVYFDL 2 25
423þ .B04 SF, CD19þ FcRL4þ 3-30 1-26 4 IgG2 5 ASGPRSGRKDYFDD 3 14
















Table 2 (continued )
Patient id Clone cell origin VH DH JH Ig SC VH-mut. VH CDR3 (aa) (þ) Length CCP2 CEP-1 cit-vim 60-75 cit-ﬁb 36-52
423þ .B06 SF, CD19þ FcRL4þ 4-39 3-3 6 IgA1 11 ASSITIFGVVKXXXGMDV 1 18
423þ .B11 SF, CD19þ FcRL4þ 3-49 5-24 4 IgA1 22 AREITSRNGYNHFAY 3 15
423þ .B12 SF, CD19þ FcRL4þ 3-53 5-18 6 IgA1 16 ASGGYSYGLDYYYAMDV 0 17
423þ .C01 SF, CD19þ FcRL4þ 1-46 3-10 2 IgA1 5 ARDQSITMVRGGPPDWNFDL 2 20
423þ .C05 SF, CD19þ FcRL4þ 4-59 1-20 4 IgG2 10 AKSSSPYDWNAPKADY 2 16
423þ .C07 SF, CD19þ FcRL4þ 3-20 6-13 6 IgG1 11 SRDVGSSFPPYYSYAMDV 1 18
423þ .D05 SF, CD19þ FcRL4þ 4-4 3-3 6 IgG3 2 AREGVGSTQGPYYYMDV 1 17
423þ .D10 SF, CD19þ FcRL4þ 4-59 3-16 4 IgG1 6 AAEVMNTDGDVDY 0 13
423þ .E01 SF, CD19þ FcRL4þ 4-39 6-13 4 IgG4 13 ARFPAGYAGSWYVDY 1 15
423þ .E02 SF, CD19þ FcRL4þ 3-21 6-13 4 IgG2 12 ASSPSGPGAAVFDY 0 14
423þ .E05 SF, CD19þ FcRL4þ 1-46 1-1 6 IgG1 4 AKESTATIGTPPEVNYYYGMDV 1 22
423þ .E08 SF, CD19þ FcRL4þ 3-30 3-16 3 IgG1 23 ARETNSYAFDI 1 11
423þ .F02 SF, CD19þ FcRL4þ 4-48 3-10 4 IgG1 14 AGVERDYVSH 2 10
423þ .F05 SF, CD19þ FcRL4þ 4-30-2 3-10 4 IgG1 12 ARVRWGSGSKIDY 3 13
423þ .F10 SF, CD19þ FcRL4þ 1-46 5-18 4 IgA2 17 ARGRGSSYGVTGFDY 2 15
423þ .G01 SF, CD19þ FcRL4þ 1-46 3-10 4 IgG2 17 ARGSGSGSYYNIDY 1 14
423þ .G03 SF, CD19þ FcRL4þ 4-4 3-9 4 IgG1 6 ARDPRRYHILTGHYEGGPSDY 5 21
423þ .G07 SF, CD19þ FcRL4þ 3-30 2-15 6 IgG1 34 AKRTGPVVVSRGGLDV 3 16
423þ .G10 SF, CD19þ FcRL4þ 3-30-3 5-18 5 IgA1 1 AREGGGYSYADNWFDP 1 16
423þ .G12 SF, CD19þ FcRL4þ 3-48 6-19 1 IgG4 6 ARDLPSRGAVAEDFDL 2 16
423þ .H08 SF, CD19þ FcRL4þ 4-59 6-19 3 IgG1 5 AREDPGQTPSGDGPDDAFDI 1 20
423þ .H09 SF, CD19þ FcRL4þ 4-31 6-6 4 IgM 30 AARIASRYFDS 2 11
423þ .H10 SF, CD19þ FcRL4þ 1-69 2-15 3 IgG1 8 ASDVARYCSGGSCYSHAFDI 2 20
423þ .H11 SF, CD19þ FcRL4þ 1-69 5-24 3 IgM 24 ARTGEMATTPNAFDIW 1 16
423-.A02 SF (CD19þ FcRL4-) 1-2 1-26 3 IgA1 15 ARGWGAAQVVFDM 1 13
423-.A05 SF (CD19þ FcRL4-) 4-34 3-3 4 IgG2 9 ARRTTAYFDFWSDYYFDS 2 18
423-.A09 SF (CD19þ FcRL4-) 1-2 1-26 4 IgA1 12 ARGFRSGSYPGY 2 12
423-.B01 SF (CD19þ FcRL4-) 3-15 4-23 4 IgG1 18 ATVRRSLSPLKY 3 12
423-.B10 SF (CD19þ FcRL4-) 4-31 2-21 6 IgA2 12 ARFRHWYYYIDV 3 12
423-.B11 SF (CD19þ FcRL4-) 4-39 3-10 4 IgA1 13 AGLYGDLFPGVMRYFDP 1 17
423-.C02 SF (CD19þ FcRL4-) 3-23 3-10 4 IgA1 19 ANAGTGYLPFDY 0 12
423-.C03 SF (CD19þ FcRL4-) 3-33 3-10 6 IgM 4 ASRGGVGGYYVKDYGMDV 2 18
423-.C04 SF (CD19þ FcRL4-) 5-51 3-22 6 IgG1 2 ARLRYYYDSSGYYYMNNYYYYYMDV 2 25
423-.C05 SF (CD19þ FcRL4-) 3-23 5-18 4 IgG2 27 AKDVVDSVMGLPFDY 1 15
423-.C09 SF (CD19þ FcRL4-) 3-33 3-16 5 IgA1 3 AREGDLIPDRFDP 2 13
423-.C12 SF (CD19þ FcRL4-) 1-18 2-2 6 IgM 5 SRVGRVPDAVRYYFYGDV 3 18
423-.D01 SF (CD19þ FcRL4-) 1-69 5-12 5 IgA1 29 ARDRRGGNRRRENWFDP 6 17
423-.D02 SF (CD19þ FcRL4-) 3-43 6-13 4 IgG2 9 AAAPGRRFDY 2 10
423-.D03 SF (CD19þ FcRL4-) 4-31 2-21 4 IgG1 16 ARGSGSGYDLAYCGGDCYFLLDK 2 23
















423-.E02 SF (CD19þ FcRL4-) 3-48 5-12 3 IgG2 20 ARGGYSGYLLTHDAFDI 2 17
423-.E07 SF (CD19þ FcRL4-) 3-30 3-3 4 IgG1 12 ANEVDFWSGYYDY 0 13
423-.E08 SF (CD19þ FcRL4-) 3-49 3-10 6 IgG1 18 SRVDRVVRGGRYYYYCMDV 4 19
423-.E12 SF (CD19þ FcRL4-) 4-61 6-19 4 IgM 6 ARVPRGWYYIDY 2 12
423-.F03 SF (CD19þ FcRL4-) 3-23 2-8 4 IgG1 10 AKPLVYARLYFDY 2 13
423-.F04 SF (CD19þ FcRL4-) 3-33 6-13 5 IgG1 15 ARDPPTSQYSSTWWTDRGFDH 3 21
423-.F06 SF (CD19þ FcRL4-) 3-11 2-21 4 IgG1 22 AREGPIVVVPVV 1 12
423-.F07 SF (CD19þ FcRL4-) 1-2 3-10 4 IgG3 14 ASGVNADGEGGPPTVGY 0 17
423-.F10 SF (CD19þ FcRL4-) 5-10-1 2-15 3 IgG1 10 AKAASRFDTFDI 2 12
423-.G03 SF (CD19þ FcRL4-) 3-33 6-19 4 IgG1 32 ARDRQWLLDY 2 10
423-.G05 SF (CD19þ FcRL4-) 3-9 3-16 5 IgM 1 AKGGWITLGSWFDP 1 14
423-.H03 SF (CD19þ FcRL4-) 1-46 6-19 4 IgG1 18 ARVVTDTAGWYHFDY 2 15
423-.H04 SF (CD19þ FcRL4-) 1-46 2-2 4 IgG3 12 ARGRLPAAIRIDFDY 3 15
423-.H06 SF (CD19þ FcRL4-) 3-30-3 6-19 3 IgG1 8 AKDGKAVDGFSGVLEM 2 16
423-.H07 SF (CD19þ FcRL4-) 4-31 3-10 4 IgG1 29 AGVERDYVSH 2 10
423-.H11 SF (CD19þ FcRL4-) 4-30-4 5-18 6 IgG1 19 ARERSYGRQYHYGMDV 4 16
Patient id Clone cell origin VH DH JH Ig SC VH-mut. VH CDR3 (aa) (þ) Length
2 03þ .A02 ST, CD19þ FcRL4þ 4-59 6-13 1 IgA1 1 ARYFFGGMSAAGSYFQH 2 17
03þ .A03 ST, CD19þ FcRL4þ 5-51 3-22 5 IgG2 26 ARLSGYYDSSGYYYPYNWFDS 1 21
03þ .A09 ST, CD19þ FcRL4þ 5-51 3-10 3 IgG1 19 VRHILWFGESDSFDI 2 15
03þ .B01 ST, CD19þ FcRL4þ 1-3 2-21 4 IgG3 25 ARSHQPYILLAGRPGV 3 16
03þ .B02 ST, CD19þ FcRL4þ 3-33 4-17 6 IgA1 25 CAGDYITRPNFSYYYYGMDV 1 20
03þ .B03 ST, CD19þ FcRL4þ 3-30-3 5-12 4 IgG1 1 AKYHVDIVATSLEYFDY 2 17
03þ .B04 ST, CD19þ FcRL4þ 3-21 3-3 5 IgA1 4 ARVWEDWFDP 1 10
03þ .B05 ST, CD19þ FcRL4þ 3-48 5-24 6 IgG1 13 AKDQPHGHIYYGLDV 3 15
03þ .B06 ST, CD19þ FcRL4þ 4-34 3-22 4 IgM 14 ARDREYYDSRGYYSFDY 3 17
03þ .B09 ST, CD19þ FcRL4þ 1-18 3-22 4 IgG1 13 AREFPYDSSGYFPGGGDY 1 18
03þ .B09 ST, CD19þ FcRL4þ 4-34 6-13 4 IgG1 9 ARGPPRAVPGTARRRYFDS 5 19
03þ .C02 ST, CD19þ FcRL4þ 3-33 2-15 5 IgG1 28 ARHGRGPSSWYDF 3 13
03þ .C03 ST, CD19þ FcRL4þ 1-69 2-15 6 IgG1 4 ARGYCSGGSCFDHYYYYGMDV 2 21
03þ .C10 ST, CD19þ FcRL4þ 1-69 1-26 4 IgG1 16 ARGFQVGTITGFDY 1 14
03þ .C11 ST, CD19þ FcRL4þ 3-20 2-2 4 IgA1 11 AKSLIGVESSFDS 1 13
03þ .C12 ST, CD19þ FcRL4þ 3-30-3 3-22 4 IgG1 10 ARGKDYYDSTGYYWGILDD 2 19
03þ .D02 ST, CD19þ FcRL4þ 3-21 1-26 4 IgG1 2 ARDRRVPYIVGATDFDY 3 17
03þ .D04 ST, CD19þ FcRL4þ 3-33 3-10 6 IgA2 31 ARGPSGMFGDLSPYFHYGVDV 2 21
03þ .D06 ST, CD19þ FcRL4þ 3-33 2-15 6 IgA1 24 ARDREAATPKYGMDV 3 15
03þ .D07 ST, CD19þ FcRL4þ 3-74 6-19 2 IgG1 6 AREVEQWLEHGVLWYFDL 2 18
03þ .D08 ST, CD19þ FcRL4þ 1-3 4-17 6 IgG3 13 AGDYITRPNFSYYYYGVDV 1 19
03þ .F01 ST, CD19þ FcRL4þ 4-39 5-24 3 IgG1 10 ARDREMGHQGIFDI 3 14
03þ .F03 ST, CD19þ FcRL4þ 1-3 2-2 6 IgG4 9 SRDRSISWDGDGMDVW 2 16
03þ .F04 ST, CD19þ FcRL4þ 4-39 2-8 4 IgG1 13 ARDKGNQPFFDY 2 12
03þ .F05 ST, CD19þ FcRL4þ 3-33 3-10 6 IgA1 29 ASRGGVGGYYVKDYGVDV 2 18
03þ .F07 ST, CD19þ FcRL4þ 4-4 3-3 6 IgG1 6 ARVSSAKTTFGVTTTWGGMDV 2 21
















Table 2 (continued )
Patient id Clone cell origin VH DH JH Ig SC VH-mut. VH CDR3 (aa) (þ) Length CCP2 CEP-1 cit-vim 60-75 cit-ﬁb 36-52
03þ .G03 ST, CD19þ FcRL4þ 3-66 2-2 6 IgA1 1 ARGGTISRYYYFGMDV 2 16
03þ .G07 ST, CD19þ FcRL4þ 1-69 6-19 6 IgA1 19 ARGAVAGRHYYFGLDV 3 16
03þ .G08 ST, CD19þ FcRL4þ 1-69 6-13 5 IgG2 4 TREAAAAGRNNWFDP 2 15
03þ .G12 ST, CD19þ FcRL4þ 1-3 2-8 4 IgG2 13 ARSHQPYILLAGTPGD 2 16
03þ .H01 ST, CD19þ FcRL4þ 4-4 3-22 4 IgG4 18 CACRYLGLDY 1 10
03þ .H04 ST, CD19þ FcRL4þ 4-34 4-23 6 IgG1 9 CARVPEVVTPRYYYYFGLDV 2 20
03-.A01 ST (CD19þ FcRL4-) 3-9 2-15 4 IgG3 33 VKDGGAGGANTFDH 2 14
03-.A02 ST (CD19þ FcRL4-) 1-69 2-21 6 IgG1 29 ASKGGDSVGYHYYMDV 2 16
03-.A03 ST (CD19þ FcRL4-) 3-23 6-13 4 IgA1 7 AKGPYSSSWYGAPFDY 1 16
03-.A04 ST (CD19þ FcRL4-) 1-69 5-24 3 IgG1 22 ARDREMGHQGIFDI 3 14
03-.A06 ST (CD19þ FcRL4-) 1-69 6-13 4 IgG1 4 ARARIAAAGNPGSFDY 2 16
03-.A08 ST (CD19þ FcRL4-) 4-59 3-10 4 IgG1 4 ARDSSYEDSVYFDY 1 14
03-.A12 ST (CD19þ FcRL4-) 1-18 2-2 4 IgG4 4 ARDEFQLPDY 1 10
03-.B06 ST (CD19þ FcRL4-) 3-23 1-26 6 IgG1 28 AKSWAILQFEPLYGMDV 1 17
03-.B11 ST (CD19þ FcRL4-) 3-53 3-16 6 IgG1 15 TRERPHEYVWGSFRRHYGMDV 6 21
03-.C01 ST (CD19þ FcRL4-) 3-49 4-17 5 IgA1 29 TIVFPELPRVPLP 1 13
03-.C03 ST (CD19þ FcRL4-) 3-23 3-22 1 IgG2 14 AKDRAGNNSGYYYVGEYFQH 3 20
03-.C05 ST (CD19þ FcRL4-) 4-34 2-8 4 IgG1 4 ARGRETYCAAGVCSSKGKRPDYFDY 5 25
03-.C08 ST (CD19þ FcRL4-) 3-30-3 3-3 4 IgA2 31 AREFEHFGSGYFPVDY 2 16
03-.C09 ST (CD19þ FcRL4-) 3-21 3-22 3 IgG2 30 ARDRFPSDDYDGPEGFDL 2 18
03-.D04 ST (CD19þ FcRL4-) 4-30-4 3-3 4 IgG1 29 ARASTLEWSYGSFDY 1 15
03-.D05 ST (CD19þ FcRL4-) 3-23 3-22 4 IgG1 19 AKADYSDSSGYKDY 2 14
03-.D07 ST (CD19þ FcRL4-) 3-74 3-3 5 IgG1 13 ASSYRIWSFDP 1 11
03-.D08 ST (CD19þ FcRL4-) 3-23 2-8 4 IgA1 1 AKPMVYARLYFDY 2 13
03-.D11 ST (CD19þ FcRL4-) 3-23 3-9 4 IgG1 19 AKDFTRYFDWLLRDLFDY 3 18
03-.E07 ST (CD19þ FcRL4-) 3-23 5-24 4 IgG1 15 ARDRMACDY 2 9
03-.E08 ST (CD19þ FcRL4-) 3-11 3-22 4 IgG2 18 ARDLTGMNSDSSGYYSDY 1 18
03-.E11 ST (CD19þ FcRL4-) 3-23 3-10 6 IgG1 22 AKAGQSPDMVRGVIRWGPKPEPKNSYYGMDV 5 31
03-.F08 ST (CD19þ FcRL4-) 3-30 1-26 4 IgA1 23 AKGVGALQAGLGSGVYYFNY 1 20
03-.F10 ST (CD19þ FcRL4-) 4-39 5-24 5 IgM 25 ARRGHYVWFDP 3 11
03-.G07 ST (CD19þ FcRL4-) 3-20 3-22 4 IgM 8 ARGPPYYISSGYYFSFDS 1 18
03-.G11 ST (CD19þ FcRL4-) 3-7 3-9 5 IgA1 6 ARTPGTFHTHNWFDP 3 15
03-.H04 ST (CD19þ FcRL4-) 4-31 3-10 5 IgG1 25 ARVVPAHHFPSGGHSSSAFNWFDP 4 24
03-.H10 ST (CD19þ FcRL4-) 3-33 3-3 4 IgA1 15 TRSLGYCTRSTCYSHEHYDH 5 20
Patient id Clone cell origin VH DH JH Ig SC VH-mut. VH CDR3 (aa) (þ) Length
6 508þ .A05 SF (CD19þ FcRL4-) 1-8 2-15 5 18 ARGHGHCSDSGCFNNWFDP 3 19
508þ .A07 SF (CD19þ FcRL4-) 3-66 3-9 4 15 ARSPTGYDILTGPFDY 1 16
508þ .A10 SF (CD19þ FcRL4-) 3-7 3-10 6 32 ARDNARAWFSHYYYGMDV 3 18
















508þ .D05 SF, CD19þ FcRL4þ 3-33 3-10 6 28 ASRGGVGGYYVKDYGMDV 2 18
508þ .D11 SF (CD19þ FcRL4þ) 3-11 3-10 6 33 ARMWFGDDHYYYGLDI 2 16
508þ .E03 SF (CD19þ FcRL4þ) 4-31 3-3 4 18 ARGQRGAILVHGYIPFFDF 3 19
508þ .E06 SF, CD19þ FcRL4þ 3-30 6-6 4 20 AKDPHSSSLISPPLFGY 2 17
508þ .E09 SF (CD19þ FcRL4þ) 3-74 3-3 1 19 ARVFKGWSSWYQGSPSEYFQH 3 21
508þ .E10 SF (CD19þ FcRL4þ) 1-69 5-18 5 21 ARGRTYTYGPMRWFDP 3 16
508þ .E11 SF (CD19þ FcRL4þ) 3-48 6-13 5 28 ARGQGRIEYNWFDL 2 14
508þ .F02 SF, CD19þ FcRL4þ 4-34 4-11 6 12 ARPTHSTVTMWYFGMDV 2 17
508þ .F04 SF, CD19þ FcRL4þ 3-30 3-10 5 19 ARDPINYYGSGSYSWNWIDP 1 20
508þ .F09 SF, CD19þ FcRL4þ 3-11 3-9 6 3 ASPSGNPNPFTMDV 0 14
508þ .F11 SF, CD19þ FcRL4þ 3-15 3-16 2 10 AREVTPHWYFDL 2 12
508þ .F12 SF, CD19þ FcRL4þ 1-46 2-15 4 12 ARGGPFTNPLCSASTCYYFDS 1 21
508-.B04 SF (CD19þ FcRL4-) 3-7 2-21 4 17 ARAADYGPVAGLFEY 1 15
508-.B09 SF (CD19þ FcRL4-) 1-8 3-10 4 17 AFHLGEYGSGSYYDLDY 1 17
508-.B10 SF (CD19þ FcRL4-) 3-21 5-12 5 28 ARVWVTGAAIFGDNWFDP 1 18
508-.C04 SF (CD19þ FcRL4-) 1-8 3-3 4 29 ARAAVDFWSGYHLEY 2 15
508-.C07 SF (CD19þ FcRL4-) 1-24 2-15 4 9 AIMGALYCSGGDCYLRGAGEFDY 1 23
508-.D06 SF (CD19þ FcRL4-) 3-48 2-8 5 14 ARGLGRLCGADNCYNWFDP 2 19
508-.D08 SF (CD19þ FcRL4-) 3-33 2-2 6 13 ARARYSSSSYGMDV 2 14
508-.D10 SF (CD19þ FcRL4-) 3-23 6-19 4 7 AREGIPVAGTDY 1 12
508-.E12 SF (CD19þ FcRL4-) 3-15 3-3 4 13 TAYRITPFGVLTGFGERPVDY 2 21
508-.F03 SF (CD19þ FcRL4-) 4-61 2-2 4 17 ARIKGGYCSYTNCKRPVPFDY 4 21
508-.F08 SF (CD19þ FcRL4-) 4-30-4 5-12 4 4 ATAPRSPTGYDSFYLDS 1 17
508-.G05 SF (CD19þ FcRL4-) 3-48 5-18 3 17 ARGRKGYSYDAFDI 3 14
508-.G08 SF (CD19þ FcRL4-) 3-30 4-17 5 5 AQDRVAALTRGGLGWFDP 2 18
508-.G09 SF (CD19þ FcRL4-) 1-69 4-11 4 4 ARELYSNYFF 1 10
508-.H07 SF (CD19þ FcRL4-) 4-34 7-27 4 4 ARLRPRLRGDLDS 4 13
508-.H08 SF (CD19þ FcRL4-) 1-18 6-19 4 4 ARTTGGDSGWFDHMDF 2 16
508-.H11 SF (CD19þ FcRL4-) 3-43 3-22 6 36 AKGLRKTDVYYDSSGFGYYYGMDV 3 24
508-.H12 SF (CD19þ FcRL4-) 1-24 3-9 4 4 ATENRFRHFWYGFDF 3 15
Patient id Clone cell origin VH DH JH Ig SC VH-mut. VH CDR3 (aa) (þ) Length
4 531þ .A01 SF (CD19þ FcRL4-) 3-21 1-1 4 15 ARCRPGSTSPEF 2 12
531þ .B07 SF (CD19þ FcRL4þ) 3-74 3-10 4 28 ARERSRIIDY 3 10
531þ .B08 SF (CD19þ FcRL4þ) 4-39 4-17 2 6 TRQWGSDYGDYWYFDL 1 16
531þ .B09 SF (CD19þ FcRL4þ) 4-39 3-3 6 11 SRDQRITILGVVSVWFGMDV 2 20
531þ .C02 SF (CD19þ FcRL4þ) 1-18 2-2 4 15 ARALLDGYCTGSSCAVGSMDY 1 21
531þ .C07 SF (CD19þ FcRL4þ) 3-33 6-19 2 19 AGSLSSGWHGNRYFDL 2 16
531þ .C08 SF, CD19þ FcRL4þ 4-34 6-6 4 17 AKGSTSSLYRHTMPYQY 3 17
531þ .C12 SF (CD19þ FcRL4þ) 3-9 1-1 4 22 ARDAKYYFDY 2 10
531þ .D03 SF (CD19þ FcRL4-) 4-34 1-26 3 5 ARSWELLLGAFDI 1 13
531þ .G01 SF, CD19þ FcRL4þ 1-69 6-13 6 28 ATAGYTSRWNPSFYHGLDV 2 19
531þ .G02 SF, CD19þ FcRL4þ 1-3 3-10 4 23 ARDYGSGNSGYFDY 1 14
531þ .G03 SF, CD19þ FcRL4þ 3-33 4-17 4 3 VTDYGDYVELGY 0 12
















Table 2 (continued )
Patient id Clone cell origin VH DH JH Ig SC VH-mut. VH CDR3 (aa) (þ) Length CCP2 CEP-1 cit-vim 60-75 cit-ﬁb 36-52
531þ .G11 SF, CD19þ FcRL4þ 3-11 3-10 5 15 ARDLLVHGVAISNWFDP 2 17
531þ .H07 SF, CD19þ FcRL4þ 4-4 5-12 6 19 ARYSGFYYHYGMDV 2 14
531-.D10 SF (CD19þ FcRL4-) 3-23 3-3 6 25 AKGGSGAFWSGYYKNYYYYYMDV 2 23
531-.D11 SF (CD19þ FcRL4-) 1-46 3-3 6 14 ARVTFESNDFGPDHFYYVLDV 2 21
531-.D12 SF (CD19þ FcRL4-) 3-69 1-26 4 3 ARHNGSYKKGYYFDY 4 15
531-.E01 SF (CD19þ FcRL4-) 3-48 3-16 4 22 AGGRSYDYFDY 1 11
531-.E02 SF (CD19þ FcRL4-) 3-23 4-23 4 2 AKEVQTEGGFDY 1 12
531-.E03 SF (CD19þ FcRL4-) 4-4 2-15 4 23 ARVVSEAAYFDN 1 12
531-.E09 SF (CD19þ FcRL4-) 3-11 5-18 4 15 ARRGGYSYRKDYFDS 4 15
531-.E12 SF (CD19þ FcRL4-) 3-23 5-18 4 4 AKDKWEGAMNPHYFDF 3 16
531-.F02 SF (CD19þ FcRL4-) 3-33 3-16 5 1 ARETFERIRLGEPNWFDP 3 18
531-.F03 SF (CD19þ FcRL4-) 4-34 3-3 4 25 TRDLSRKIFGVVKPAFYFDY 4 20
531-.F05 SF (CD19þ FcRL4-) 3-48 3-22 4 5 AREGEGDLYYYDSSGYYYL 1 19
531-.F07 SF (CD19þ FcRL4-) 1-2 3-22 3 3 ASKKEGVLPLDPFDI 2 15
531-.G03 SF (CD19þ FcRL4-) 4-31 4-11 6 2 GRTLATVPMDV 1 11
531-.G11 SF (CD19þ FcRL4-) 3-23 6-19 4 9 AKGSVAGPFDY 1 11
531-.H07 SF (CD19þ FcRL4-) 1-18 3-3 3 9 ARAEGAVTIDDAFDI 1 15

















Number of sequences and recombinant monoclonal antibodies generated from FcRL4þ and FcRL4- B cells respectively.








1 ST RA pos pos positive 1 59 34 26
negative 1 33 23 17
2 ST RA pos pos positive 1 33 ND ND
negative 1 28 ND ND
3 SF RA neg neg positive 1 33 ND ND
negative 1 32 ND ND
4 SF RA neg neg positive 1 15 ND ND
negative 1 16 ND ND
5 SF RA pos pos positive 1 30 22 10
negative 1 33 25 10
6 SF RA na pos positive 1 16 ND ND
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